ArticleScientific reports2026
Indirubin treatment was associated with modulation of the PI3K/AKT and MAPK pathways and induction of apoptosis and autophagy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autophagy: mechanisms, roles in human diseases, and therapeutic perspectives.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigated the effects of indirubin on autophagy and apoptosis in cervical cancer models, with a focus on elucidating the underlying molecular mechanisms. A xenograft tumor model in BALB/c-Nude mice and in vitro experiments using HeLa cell lines were employed. Indirubin treatment demonstrated a concentration-dependent inhibition of cervical cancer cell growth, accompanied by the induction of apoptosis and autophagy. Mechanistic analysis revealed that these effects were associated with the modulation of the PI3K/AKT signaling axis. This was evidenced by enhanced autophagic flux, indicated by an increased LC3-II/LC3-I ratio and decreased P62 expression, and concurrent induction of mitochondrial apoptosis, marked by upregulated pro-apoptotic Bax and downregulated anti-apoptotic Bcl-2 levels. Furthermore, indirubin treatment was linked to the inhibition of the MEKK1/SEK1/JNK/AP-1 signaling pathway, which may also contribute to its anti-tumor effects. These findings suggest that the anti-tumor activity of indirubin is associated with the regulation of the PI3K/AKT and MAPK pathways, the enhancement of autophagy, and the promotion of apoptosis, providing a theoretical basis for its therapeutic potential in cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.